Announcing a new publication for Acta Materia Medica journal.

Endocrine therapy that blocks oestrogen receptor signalling has been effective for decades as a primary treatment choice for breast cancer patients expressing the oestrogen receptor.

However, the issue of drug resistance poses a significant clinical challenge.

It is therefore critically important to create new therapeutic agents that can suppress ERα activity, particularly in cases of ESR1 mutations.

This review article highlights recent efforts in drug development of next generation ER-targeted agents, including oral selective ER degraders, proteolysis-targeting chimera ER degraders, and other innovative molecules, such as complete oestrogen receptor antagonists and selective oestrogen receptor covalent antagonists.

The drug design, efficacy, and clinical trials for each compound are detailed.

Source: Compuscript LTD